{Reference Type}: Journal Article
{Title}: Splice-switching antisense oligonucleotides for pediatric neurological disorders.
{Author}: Zhang X;
{Journal}: Front Mol Neurosci
{Volume}: 17
{Issue}: 0
{Year}: 2024
{Factor}: 6.261
{DOI}: 10.3389/fnmol.2024.1412964
{Abstract}: Pediatric neurological disorders are frequently devastating and present unmet needs for effective medicine. The successful treatment of spinal muscular atrophy with splice-switching antisense oligonucleotides (SSO) indicates a feasible path to targeting neurological disorders by redirecting pre-mRNA splicing. One direct outcome is the development of SSOs to treat haploinsufficient disorders by targeting naturally occurring non-productive splice isoforms. The development of personalized SSO treatment further inspired the therapeutic exploration of rare diseases. This review will discuss the recent advances that utilize SSOs to treat pediatric neurological disorders.